 Proto-Oncogene Proteins c-akt
"Proto-Oncogene Proteins c-akt" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein-serine-threonine kinases that contain PLECKSTRIN HOMOLOGY DOMAINS and are activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. They play a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells.
| Descriptor ID |
D051057
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.755 D12.776.476.565 D12.776.624.664.700.168
|
| Concept/Terms |
Proto-Oncogene Proteins c-akt- Proto-Oncogene Proteins c-akt
- Proto Oncogene Proteins c akt
- c-akt, Proto-Oncogene Proteins
- Protein Kinase B
- Proto-Oncogene Protein RAC
- Proto Oncogene Protein RAC
- RAC, Proto-Oncogene Protein
- Proto-Oncogene Protein Akt
- Akt, Proto-Oncogene Protein
- Proto Oncogene Protein Akt
- Rac Protein Kinase
- akt Proto-Oncogene Protein
- Protein, akt Proto-Oncogene
- Proto-Oncogene Protein, akt
- akt Proto Oncogene Protein
- RAC-PK Protein
- RAC PK Protein
- Related to A and C-Protein
- Related to A and C Protein
- c-akt Proto-Oncogene Protein
- Protein, c-akt Proto-Oncogene
- Proto-Oncogene Protein, c-akt
- c akt Proto Oncogene Protein
- c-akt Protein
- Protein-Serine-Threonine Kinase (Rac)
Proto-Oncogene Proteins c-akt1- Proto-Oncogene Proteins c-akt1
- Proteins c-akt1, Proto-Oncogene
- Proto Oncogene Proteins c akt1
- c-akt1, Proto-Oncogene Proteins
- AKT1 Protein Kinase
- Rac-PK alpha Protein
- Rac PK alpha Protein
- alpha Protein, Rac-PK
- Protein Kinase B alpha
- Akt-alpha Protein
- Akt alpha Protein
Proto-Oncogene Proteins c-akt2- Proto-Oncogene Proteins c-akt2
- Proteins c-akt2, Proto-Oncogene
- Proto Oncogene Proteins c akt2
- c-akt2, Proto-Oncogene Proteins
- Protein Kinase B beta
- Rac-PK beta Protein
- Rac PK beta Protein
- AKT2 Protein Kinase
- Akt-beta Protein
- Akt beta Protein
Proto-Oncogene Proteins c-akt3- Proto-Oncogene Proteins c-akt3
- Proteins c-akt3, Proto-Oncogene
- Proto Oncogene Proteins c akt3
- c-akt3, Proto-Oncogene Proteins
- Akt-gamma Protein
- Akt gamma Protein
- AKT3 Protein Kinase
- Protein Kinase B gamma
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-akt".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-akt".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-akt" by people in this website by year, and whether "Proto-Oncogene Proteins c-akt" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 4 | 4 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 8 | 8 | | 2003 | 0 | 7 | 7 | | 2004 | 0 | 15 | 15 | | 2005 | 1 | 12 | 13 | | 2006 | 1 | 10 | 11 | | 2007 | 3 | 7 | 10 | | 2008 | 6 | 8 | 14 | | 2009 | 4 | 10 | 14 | | 2010 | 7 | 12 | 19 | | 2011 | 4 | 10 | 14 | | 2012 | 2 | 8 | 10 | | 2013 | 3 | 13 | 16 | | 2014 | 4 | 13 | 17 | | 2015 | 5 | 20 | 25 | | 2016 | 3 | 8 | 11 | | 2017 | 9 | 3 | 12 | | 2018 | 2 | 7 | 9 | | 2019 | 5 | 5 | 10 | | 2020 | 3 | 4 | 7 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 9 | 10 | | 2023 | 0 | 3 | 3 | | 2024 | 5 | 2 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-akt" by people in Profiles.
-
Lyu C, Vaddi PK, Elshafae S, Pradeep A, Ma D, Chen S. Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development. Oncogene. 2025 Feb; 44(5):322-335.
-
Sun X, Moreno Caceres S, Yegambaram M, Lu Q, Pokharel MD, Boehme JT, Datar SA, Aggarwal S, Wang T, Fineman JR, Black SM. The mitochondrial redistribution of ENOS is regulated by AKT1 and dimer status. Nitric Oxide. 2024 Nov 01; 152:90-100.
-
Ghosh S, Sharma R, Bammidi S, Koontz V, Nemani M, Yazdankhah M, Kedziora KM, Stolz DB, Wallace CT, Yu-Wei C, Franks J, Bose D, Shang P, Ambrosino HM, Dutton JR, Geng Z, Montford J, Ryu J, Rajasundaram D, Hose S, Sahel JA, Puertollano R, Finkel T, Zigler JS, Sergeev Y, Watkins SC, Goetzman ES, Ferrington DA, Flores-Bellver M, Kaarniranta K, Sodhi A, Bharti K, Handa JT, Sinha D. The AKT2/SIRT5/TFEB pathway as a potential therapeutic target in non-neovascular AMD. Nat Commun. 2024 Jul 21; 15(1):6150.
-
Pearson AD, DuBois SG, Macy ME, de Rojas T, Donoghue M, Weiner S, Knoderer H, Bernardi R, Buenger V, Canaud G, Cantley L, Chung J, Fox E, Friend J, Glade-Bender J, Gorbatchevsky I, Gore L, Gupta A, Hawkins DS, Juric D, Lang LA, Leach D, Liaw D, Lesa G, Ligas F, Lindberg G, Lindberg W, Ludwinski D, Marshall L, Mazar A, McDonough J, Nysom K, Ours C, Pappo A, Parsons DW, Rosenfeld A, Scobie N, Smith M, Taylor D, Weigel B, Weinstein A, Karres D, Vassal G. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3? inhibitors in children and adolescents with cancer. Eur J Cancer. 2024 Aug; 207:114145.
-
Farrell KB, Das S, Nordeen SK, Lambert JR, Thamm DH. VDX-111 targets proliferative pathways in canine cancer cell lines. PLoS One. 2024; 19(5):e0303470.
-
Bhartiya P, Jaiswal A, Negi M, Kaushik N, Ha Choi E, Kumar Kaushik N. Unlocking melanoma Suppression: Insights from Plasma-Induced potent miRNAs through PI3K-AKT-ZEB1 axis. J Adv Res. 2025 Feb; 68:147-161.
-
He F, Laranjeira AB, Kong T, Lin S, Ashworth KJ, Liu A, Lasky NM, Fisher DA, Cox MJ, Fulbright MC, Antunes-Heck L, Yu L, Brakhane M, Gao B, Sykes SM, D'Alessandro A, Di Paola J, Oh ST. Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms. J Clin Invest. 2024 Feb 01; 134(3).
-
Alanazi AH, Chastain DB, Rudraraju M, Parvathagiri V, Shan S, Lin X, Henao-Mart?nez AF, Franco-Paredes C, Narayanan SP, Somanath PR. A multi-arm, parallel, preclinical study investigating the potential benefits of acetazolamide, candesartan, and triciribine in combination with fluconazole for the treatment of cryptococcal meningoencephalitis. Eur J Pharmacol. 2023 Dec 05; 960:176177.
-
Rose MM, Nassar KW, Sharma V, Schweppe RE. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition. Med Oncol. 2023 Sep 15; 40(10):299.
-
McCaleb MR, Miranda AM, Ratliff KC, Torres RM, Pelanda R. CD19 Is Internalized Together with IgM in Proportion to B Cell Receptor Stimulation and Is Modulated by Phosphatidylinositol 3-Kinase in Bone Marrow Immature B Cells. Immunohorizons. 2023 01 01; 7(1):49-63.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|